Other potential AD plasma biomarkers could be related to abnormal astroglia activation response in neurodegenerative diseases (e.g., GFAP) [33,34], triggering receptor expressed on myeloid cells 2 (TREM2)) [35]. This evidence concerns the gene TREM2 and neurodegenerative disease.